Navigation Links
Thomson Reuters Predicts Nobel Laureates
Date:9/23/2009

PHILADELPHIA and LONDON, Sept. 24 /PRNewswire/ -- Thomson Reuters today announced the 2009 Thomson Reuters Citation Laureates -- researchers likely to be in contention for Nobel honors -- in anticipation of this year's Nobel Prize winners in the sciences and in economics to be announced from October 5-12.

Thomson Reuters is the only organization to use quantitative data to make annual predictions of Nobel Prize winners.

Each year, data from ISI Web of Knowledge((R)), the world's largest citation environment of the highest quality scholarly literature, is used to quantitatively determine the most influential researchers in the Nobel categories of Physiology or Medicine, Physics, Chemistry, and Economics. These high-impact researchers are named Thomson Reuters Citation Laureates and predicted to be Nobel Prize winners, either this year or in the near future, based on the citation impact of their published research.

Since 2002, 15 Citation Laureates have gone on to win Nobel Prizes.

"We choose our Citation Laureates by assessing citation counts and the number of high-impact papers they have produced while identifying discoveries or themes that may be considered worthy of recognition by the Nobel Committee," said David Pendlebury, Citation Analyst at Thomson Reuters. "A strong correlation exists between citations in scientific literature and peer esteem. Professional awards, like the Nobel Prize, are also a reflection of peer esteem."

The Thomson Reuters Citation Laureates typically rank among the top one-tenth of one percent (0.1%) of researchers in their fields, based on citations of their published papers over the last two or three decades.

The 2009 Thomson Reuters Citation Laureates by Nobel Prize category are as follows:

Chemistry

    Michael Gra
'/>"/>
SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
2. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
3. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
4. Thomson Scientific Salutes Nobel Laureate Prize Winners, Many of Whom Were Selected as Thomson Scientific Laureates in 2006
5. Thomson Scientific Begins Expansion of Web of Science
6. Thomson Reuters Launches New Biomarkers Solution
7. The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results
8. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
9. Despite Decline in Share of Global Output, U.S. Science Impact Still Strong, Says Thomson Reuters
10. Thomson Reuters Names Hottest Researchers and Papers of 2007-2008
11. APS Healthcare and Thomson Reuters to Manage New York States Medicaid Clinical Best Practices Review Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... RIDGE, N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today ... mg (referred to as Somatuline®) was approved by ... the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in ... locally advanced or metastatic disease to improve progression-free ...
(Date:12/17/2014)... Xeno Diagnostics has again received ... recent COLA inspection. Xeno has met all criteria ... accreditation organization. Accreditation is earned only by laboratories ... operations, demonstrate continued accuracy in the performance of ... survey. , While the Laboratory Excellence ...
(Date:12/17/2014)... , Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... gynecologic disease, today announced the next step in its ... bio-analytics solutions provider with the naming of current Chief ... Chief Executive Officer, while current Chairman of the Board ... serve as Chairman. These changes are effective January 1, ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... Capital Investments,Inc. (AMEX: MGT ), a technology ... sector, today reported financial results,for the first quarter ... on,strategic milestones., Tim Paterson-Brown, MGT Chairman and ... turning point for our subsidiaries, Medicsight and,Medicexchange. In ...
... Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ) announced today ... Rodman & Renshaw 5th Annual Global,Healthcare Conference on Tuesday, ... Beach Plaza Hotel in Monte Carlo, Monaco., The ... be,accessed under "Calendar of Events" in the Idenix Investor ...
... MedQuist Inc.,(Pink Sheets: MEDQ), the largest Medical Transcription Service ... its Form 10-Q quarterly,report with the U.S. Securities and ... Revenue for the first quarter of 2008 was $83.7M ... decrease in revenue of $5.4M or 6% from,the prior ...
Cached Biology Technology:MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments 2MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments 3MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments 4MedQuist Reports First Quarter 2008 Results 2MedQuist Reports First Quarter 2008 Results 3MedQuist Reports First Quarter 2008 Results 4MedQuist Reports First Quarter 2008 Results 5MedQuist Reports First Quarter 2008 Results 6MedQuist Reports First Quarter 2008 Results 7MedQuist Reports First Quarter 2008 Results 8MedQuist Reports First Quarter 2008 Results 9
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... 4, 2014  Tute Genomics, a leader in cloud-based ... Series A1 funding led by UK-based Eurovestech. Peak Ventures ... the investment round. "We are at a ... next-generation sequencing and seeks new approaches for the diagnosis, ... , MD MBA, and CEO of Tute Genomics. "One ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... a Tiger,s feet were built the same way as a mongoose,s ... feet to support the big cat,s weight. But they,re not. ... feet are put together across the four-legged animal kingdom, but until ... of the foot that bear the brunt of the animal,s walking ...
... advance toward scavenging energy from walking, breathing, and other ... phones and heart pacemakers. In a study in ACS, ... of flexible, biocompatible rubber films for use in implantable ... used, for instance, to harvest energy from the motion ...
... research suggests that nitric oxide may play a role in ... Mittal et al, "Inhibition of inducible nitric oxide controls pathogen ... coli K1 in neonatal meningitis," appears in the March ... Bacterial meningitis, or inflammation of the membranes that ...
Cached Biology News:The bigger the animal, the stiffer the 'shoes' 2Treating neonatal meningitis -- is nitric oxide a foe or a friend to bacteria? 2
MHC Volumes 1 & 2...
...
... Johnstone and M.W. Turner (1997). • ... methods used in the production of ... in immunoassays, the standardisation of antibodies ... including amplification systems, enzyme immunoassays for ...
... PAGE Cleavable ICAT Reagent ... Protein ID and Quantitation ... Electrophoresis (PAGE), isotope-coded affinity ... technology to facilitate the ...
Biology Products: